Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.

摘要: BACKGROUND The objective of this trial was to evaluate the activity and safety one newer platinum-based doublets as a neoadjuvant regimen in patients with unresectable Stage IIIA-bulky N2 IIIB nonsmall cell lung carcinoma (NSCLC). METHODS From June 1996 April 2000, 129 consecutive locally advanced NSCLC were treated gemcitabine, 1000 mg/m2 on Days 1 8 cisplatin, 70 Day 2 (GC) 21-day treatment cycle, for 4 cycles, part combined-modality approach. RESULTS After induction chemotherapy, 80 (62%; 95% confidence interval, 53.6–70.4%) achieved partial response, 43 (33%) had stable disease, 6 (5%) disease progression during chemotherapy. Forty (31%), considered resectable underwent thoracotomy. Complete resectability obtained 38 (29%), 2% achieving pathologic complete response. After surgery, 9 Mountain Classification IIIA received definitive adjuvant radiotherapy. Forty-six 52 24 37 who not suitable surgery The median time 11.4 months, survival 19.4 months (range, 1.2–55.2 + months), 1-year rate 74%. lungs brain (21%) main sites recurrence. Major toxicity comprised Grade 3–4 thrombocytopenia, which occurred 34 (27%). CONCLUSIONS GC administered according 3-week schedule highly active safe primary, unresectable, NSCLC. Cancer 2003;98:128–34. © 2003 American Society. DOI 10.1002/cncr.11460